Table 1.
Clinical studies with NK-92 and haNK cells
| Trial identifier: ClinicalTrials.gov: | Disease condition | NK cell | Combination agent | Phase | Status |
|---|---|---|---|---|---|
| NCT02465957 | stage IIIB and IV Merkel cell carcinoma | NK-92 | phase 2 | active, not recruiting | |
| NCT02727803 | myelodysplastic syndrome, leukemia, lymphoma, MM | NK-92 | biological: anti-thymocyte globulin, rituximab | phase 2 | active, recruiting |
| drug: busulfan, clofarabine, cyclophosphamide, fludarabine phosphate, melphalan | |||||
| radiation: total-body irradiation | |||||
| procedure: umbilical cord blood transplantation | |||||
| NCT03136406 | pancreatic cancer | NK-92 | drug: cyclophosphamide, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel | phase 1/2 | active, not recruiting |
| biological: bevacizumab, avelumab, N-803, Ad-CEA, RAS-yeast | |||||
| NCT03387085 | TNBC | haNK | drug: aldoxorubicin HCl, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel | phase 1/2 | unknown |
| biological: N-803, Ad-CEA, Ad-brachyury, Ad-MUC1, RAS-yeast, CEA-yeast, brachyury-yeast, avelumab, bevacizumab | |||||
| procedure: SBRT | |||||
| NCT03563157 | metastatic CRC | haNK | drug: aldoxorubicin HCl, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel | phase 1/2 | active, not recruiting |
| biological: N-803, Ad-CEA, Ad-brachyury, Ad-MUC1, yeast-RAS, yeast-CEA, yeast-brachyury, avelumab, bevacizumab | |||||
| procedure: SBRT | |||||
| NCT03387111 | squamous cell carcinoma | haNK | drug: aldoxorubicin HCl, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel | phase 1/2 | active, not recruiting |
| biological: N-803, Ad-CEA, Ad-brachyury, Ad-MUC1, yeast-RAS, yeast-CEA, yeast-brachyury, avelumab, bevacizumab, necitumumab | |||||
| procedure: SBRT | |||||
| NCT03329248 | pancreatic cancer | haNK | biological: N-803, Ad-CEA, RAS-yeast, avelumab, bevacizumab | phase 1/2 | active, not recruiting |
| drug: capecitabine, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, Lovaza, oxaliplatin | |||||
| procedure: SBRT | |||||
| NCT03853317 | Merkel cell carcinoma | haNK | biological: avelumab, N-803 | phase 2 | active, recruiting |
MM, multiple myeloma; Ad, adenovirus; CEA, carcinoembryonic antigen; RAS, rat sarcoma virus; TNBC, triple-negative breast cancer; haNK, high-affinity natural killer; SBRT, stereotactic body radiation therapy; CRC, colorectal cancer; MUC1, mucin 1.